Management

Image of Michael H. Tardugno

Mr. Tardugno's career has been exclusively focused in healthcare with 30 years of experience in the pharmaceutical and medical device industries. Prior to joining the company in 2007, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal drug company. He was a founding member of management of Songbird Hearing, Inc., a privately held start-up, and held the positions of Senior Vice President of Technical Operations at Bristol-Myers Squibb and Senior Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations. Mr. Tardugno holds a B.S. from St. Bonaventure University and attended the Harvard Business School executive program.
 

Recent Stock Transactions by Michael H. Tardugno
Date Type Shares Traded Price Range
Oct 7, 2016 Buy 10,000 1.14
Aug 16, 2016 Buy 5,000 1.25
Jun 16, 2016 Buy 7,500 1.35
Feb 19, 2016 Buy 3,000 1.27
Feb 17, 2016 Buy 2,000 1.27
Feb 16, 2016 Buy 4,500 1.20
Feb 12, 2016 Buy 6,500 1.13
Feb 2, 2016 Acquisition (Non Open Market) 25,000 1.33
Aug 10, 2015 Buy 5,000 2.29
Aug 15, 2014 Buy 4,000 3.12
Jun 20, 2014 Acquisition (Non Open Market) 12,000 3.50
Jun 11, 2014 Buy 5,000 3.20
Mar 14, 2014 Buy 4,000 3.84
Nov 19, 2013 Buy 2,800 3.59
Aug 16, 2013 Buy 5,000 1.08
Jun 12, 2013 Buy 10,000 1.35
Dec 7, 2012 Option Execute 17,271 2.77
Sep 14, 2012 Buy 5,000 5.03 - 5.04
Dec 5, 2011 Buy 5,000 2.16 - 2.21
May 26, 2011 Buy 17,271 2.77
Mar 23, 2011 Acquisition (Non Open Market) 17,083 2.40
May 7, 2010 Buy 4,000 3.95
Feb 19, 2010 Acquisition (Non Open Market) 17,412 2.94
Jan 19, 2010 Option Execute 16,667 n/a
Nov 19, 2009 Buy 6,000 3.21
Aug 17, 2009 Buy 5,000 3.30
Mar 17, 2009 Buy 3,750 2.56
Jan 19, 2009 Acquisition (Non Open Market) 25,000 2.72
Nov 14, 2008 Buy 3,000 2.83
Jun 16, 2008 Acquisition (Non Open Market) 2,500 4.38 - 4.40
May 17, 2007 Buy 2,384 4.81 - 4.82
Feb 23, 2007 Buy 7,616 3.46
Image of Nicholas Borys M.D.
Nicholas Borys, M.D. joined Celsion on October 1, 2007 as Vice President and Chief Medical Officer. In this position Dr. Borys manages the clinical development program for Celsion. Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc, has accumulated extensive experience in all phases of pharmaceutical development with a focus in oncology while holding increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys attended Rutgers University and holds an M.D. Degree from American University of the Caribbean.
Recent Stock Transactions by Nicholas Borys M.D.
Date Type Shares Traded Price Range
Feb 2, 2016 Acquisition (Non Open Market) 12,000 1.33
Dec 12, 2011 Buy 5,000 2.00
Mar 23, 2011 Acquisition (Non Open Market) 2,500 2.40
Sep 22, 2010 Buy 1,650 3.03 - 3.04
Feb 19, 2010 Acquisition (Non Open Market) 7,537 2.94
Jan 19, 2009 Acquisition (Non Open Market) 5,000 2.72
Nov 20, 2008 Buy 5,596 2.50
Nov 19, 2008 Buy 404 2.50
Jun 18, 2008 Buy 3,000 4.10
May 21, 2008 Statement of Ownership 0 n/a
Image of Jeffrey W. Church C.P.A.

Jeffrey W. Church was appointed Senior Vice President, Corporate Strategy and Investor Relations on July 8, 2011. Mr. Church joined Celsion in July 2010 as Vice President and Chief Financial Officer. Mr. Church brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining the Company, Mr. Church held senior financial executive positions with several private and public clinical stage Life Science companies including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm, Price Waterhouse. Mr. Church holds a B.S. degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.

Recent Stock Transactions by Jeffrey W. Church C.P.A.
Date Type Shares Traded Price Range
Feb 2, 2016 Acquisition (Non Open Market) 12,000 1.33
Jun 20, 2014 Acquisition (Non Open Market) 10,500 3.50
Sep 14, 2012 Buy 2,000 4.93
May 26, 2011 Buy 3,454 2.77
Mar 23, 2011 Acquisition (Non Open Market) 3,333 2.40
Feb 25, 2011 Acquisition (Non Open Market) 10,000 n/a
Jul 6, 2010 Acquisition (Non Open Market) 25,000 n/a
Image of Khursheed Anwer

Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Scientific Officer, EGEN, upon Celsion’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Scientific Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer is an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.

Recent Stock Transactions by Khursheed Anwer
Date Type Shares Traded Price Range
Jun 20, 2014 Acquisition (Non Open Market) 5,000 3.50

Stock transaction information provided by EDGAR Online. Celsion Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Share This